Document is current
Any future updates will be listed below
-
Authors
Zhang, Zhaoyue
TeSlaa, Tara
Xu, Xincheng
Zeng, Xianfeng
Yang, Lifeng
Xing, Gang https://orcid.org/0000-0001-8857-9421
Tesz, Gregory J.
Clasquin, Michelle F. https://orcid.org/0000-0002-5361-6859
Rabinowitz, Joshua D. https://orcid.org/0000-0002-1247-4727
-
Funding
Funding for this research was provided by:
Pioneer Fund (1DP1DK113643)
Ruth L Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship F32
- License Information
-
More Information
Article History
Received: 10 August 2021
Accepted: 30 September 2021
First Online: 29 November 2021
Competing interests
: G.X., G.J.T. and M.F.C. are current employees of Pfizer and may be Pfizer shareholders. J.D.R. is a consultant and received research funding from Pfizer and is an adviser and stock owner in Colorado Research Partners, L.E.A.F. Pharmaceuticals, Rafael Pharmaceuticals, Barer Institute and its subsidiaries, Serien Therapeutics, Toran, Kadmon Pharmaceuticals and Agios Pharmaceuticals. J.D.R. is co-inventor of SHIN2 and related SHMT inhibitors, which have been patented by Princeton University. The remaining authors declare no competing interests.
